



Pfizer Australia Pty Ltd  
Level 17, 151 Clarence Street  
Sydney, NSW 2000

27 July 2022

Dear Healthcare Professional,

**Shelf-life extension of PAXLOVID™ (nirmatrelvir 150 mg/ritonavir 100 mg), film coated tablets  
AUST R 377572**

We would like to inform you that on 20 July 2022 a new shelf life for PAXLOVID has been approved in Australia by the Therapeutic Goods Administration (TGA).

The shelf life has been extended from 12 months to 18 months. The storage conditions of 'Store below 25 degrees Celsius' remain unchanged.

This 6-month extension may be applied retrospectively to PAXLOVID products manufactured prior to this approval. Cartons with an expiry date of August 2022 through to April 2023 printed on the carton or blisters may remain in use for 6 months beyond the printed date, as long as the approved storage conditions have been maintained. Updated expiry dates are shown below.

<b>Printed Date</b>	<b>Updated Expiry Date</b>
August 2022	February 2023
November 2022	May 2023
December 2022	June 2023
January 2023	July 2023
February 2023	August 2023
March 2023	September 2023
April 2023	October 2023

**PLEASE REVIEW THE CURRENT AUSTRALIAN PRODUCT INFORMATION BEFORE PRESCRIBING OR DISPENSING.**

The Australian Product Information and Consumer Medicine Information can be found at <https://www.tga.gov.au/>. The PAXLOVID Australian Product Information for Healthcare professionals is also available by scanning the QR Code below:



## **Adverse Event Reporting**



PAXLOVID is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems). Alternatively, any adverse events which are experienced with PAXLOVID can be reported to Pfizer on 1800 675 229 or by email to [AUS.AEreporting@pfizer.com](mailto:AUS.AEreporting@pfizer.com)

## **Medical Enquiries**

Please direct any medical enquiries to Medical Information on 1800 675 229 or via [www.pfizermedicalinformation.com.au](http://www.pfizermedicalinformation.com.au)

Yours sincerely,

A handwritten signature in black ink, appearing to read 'D. Grolman', written in a cursive style.

**Dr David Grolman**  
Medical Director  
Hospital Business Unit  
Pfizer Australia